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ABSTRACT
Although nociceptin/orphanin FQ (N/OFQ) influences dopamine (DA) neuronal activity,
it is not known whether N/OFQ acts directly on DA neurons, indirectly by means of local
circuitry, or both. We used two parallel approaches, dual in situ hybridization (ISH) and
neurotoxic lesions of DA neurons by using 6-hydroxydopamine (6-OHDA), to ascertain
whether N/OFQ and the N/OFQ receptor (NOP) mRNA are expressed in DA neurons in the
ventral tegmental area (VTA) and substantia nigra compacta (SNc). In the VTA and SNc,
small populations (6–10%) of N/OFQ-containing neurons coexpressed mRNA for tyrosine
hydroxylase (TH), the rate-limiting enzyme for DA synthesis. Similarly, very few (1–2%)
TH-positive neurons contained N/OFQ mRNA signal. A majority of NOP-positive neurons
(75%) expressed TH mRNA and roughly half of the TH-containing neurons expressed NOP
mRNA. Many N/OFQ neurons (50–60%) expressed glutamic acid decarboxylase 65 and 67
mRNAs, markers for -aminobutyric acid (GABA) neurons. In the 6-OHDA lesion studies,
NOP mRNA levels were nearly 80 and 85% lower in the VTA and SNc, respectively, on the
lesioned side. These lesions appear to lead to compensatory changes, with N/OFQ mRNA
levels approximately 60% and 300% higher in the VTA and SNc, respectively, after 6-OHDA
lesions. Finally, N/OFQ-stimulated [35S]guanylyl-5-O-(-thio)-triphosphate levels were de-
creased in the VTA and SNc but not the prefrontal cortex after 6-OHDA lesions. Accordingly,
it appears that N/OFQ mRNA was found largely on nondopaminergic (i.e., GABA) neurons,
whereas NOP mRNA was located on DA neurons. N/OFQ is in a position to influence DA
neuronal activity by means of the NOP located on DA neurons. J. Comp. Neurol. 444:
358–368, 2002. © 2002 Wiley-Liss, Inc.
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Three opioid receptors known as , , and  have been
cloned (Evans et al., 1992; Kieffer et al., 1992; Chen et al.,
1993; Meng et al., 1993; Thompson et al., 1993; Wang et
al., 1993; Yasuda et al., 1993; Fukuda et al., 1994). With
polymerase chain reaction amplification and low strin-
gency hybridization techniques, several laboratories de-
tected human, mouse (Mollereau et al., 1994), and rat
(Bunzow et al., 1994; Chen et al., 1994; Fukuda et al.,
1994; Wang et al., 1994; Wick et al., 1994) cDNAs encod-
ing a novel receptor, which will be referred to as NOP (also
known as ORL1). Approximately 65% of the residues
within the membrane-spanning region of the NOP are
similar to , , and  opioid receptors (Mollereau et al.,
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1994; Lachowicz et al., 1995). Despite this similarity, clas-
sic opioid ligands do not specifically bind to the NOP with
any significant affinity (Fukuda et al., 1994; Mollereau et
al., 1994; Wang et al., 1994).
A 17 amino acid peptide termed orphanin FQ or noci-
ceptin (N/OFQ) was discovered to be the high-affinity en-
dogenous ligand for the NOP (Meunier et al., 1995; Rein-
scheid et al., 1995). There is a significant amino acid
sequence similarity between N/OFQ and the endogenous
opioid peptides. This resemblance is particularly striking
in the case of dynorphin A(1-17). Orphanin FQ and dynor-
phin A have the same amino acid length, a similar amino
acid motif (“Phe-Gly-Gly-Phe” in N/OFQ and “Tyr-Gly-
Gly-Phe” in the opioid peptides) at the amino terminal and
similar groups of positive charges in the midportion and
C-terminal end (Meunier et al., 1995; Reinscheid et al.,
1995). Like other opioid ligands, N/OFQ modulates Ca2
channels (Knoflach et al., 1996; Connor and Christie,
1999), activates inward rectifying K channels (Connor et
al., 1996; Vaughan and Christie, 1996) and inhibits cAMP
production (Meunier et al., 1995; Reinscheid et al., 1995).
Opioid ligands exhibit varying degrees of affinity for each
of the opioid receptors (Mansour et al., 1995). Despite the
aforementioned similarities between opioid and the
opioid-like orphanin system, N/OFQ does not bind with
any appreciable affinity to the classic opioid receptors
(Reinscheid et al., 1995). Accordingly, the orphanin sys-
tem, although resembling the opioid system in many
ways, has evolved into a distinct and independent system
(Meng et al., 1996; Reinscheid et al., 1996; Danielson and
Dores, 1999).
The widespread anatomic distribution of the orphanin
system (Bunzow et al., 1994; Fukuda et al., 1994; Molle-
reau et al., 1994; Wick et al., 1994; Lachowicz et al., 1995;
Neal et al., 1999a, b) suggests involvement in a broad
array of neurologic functions. For example, N/OFQ admin-
istration (i.c.v.) decreases nociceptive threshold in the ro-
dent tail flick test (Meunier et al., 1995; Reinscheid et al.,
1995; Rossi et al., 1996), increases feeding (Pomonis et al.,
1996; Stratford et al., 1997), activates neuroendocrine re-
sponse to stress (Devine et al., 2001), decreases anxiety in
behavioral tests (Jenck et al., 1997; Griebel et al., 1999),
impairs motor coordination (Devine et al., 1996b), alters
locomotion (Reinscheid et al., 1995; Devine et al., 1996b;
Florin et al., 1996, 1997b), and influences learning and
memory processes (Sandin et al., 1997; Manabe et al.,
1998; Hiramatsu and Inoue, 1999).
Orphanin FQ and NOP are moderately to heavily ex-
pressed in dopamine (DA) -rich areas such as the ventral
tegmental area (VTA), substantia nigra compacta (SNc),
and prefrontal cortex (PFC; Florin et al., 1997a; Neal et
al., 1999a, b). The orphanin system is, therefore, in a
position to influence DA neuronal activity and several
studies have shown a functional interaction between these
two systems. Local N/OFQ application into the striatum
increases DA levels as well as locomotor activity (Konya et
al., 1998). Additionally, N/OFQ administration into the
VTA or lateral ventricle decreases accumbal DA levels as
measured with microdialysis (Murphy et al., 1996; Mur-
phy and Maidment, 1999). Alterations in DA release are
typically associated with motivational states; however,
N/OFQ administration (i.c.v.) fails to produce conditioned
place preference or aversion (Devine et al., 1996a). Despite
these initial studies, the role of the N/OFQ system in
mediating DA neuronal function is far from understood.
To better understand the anatomic relationships be-
tween the orphanin and DA systems, two parallel ap-
proaches were used to ascertain whether N/OFQ and NOP
mRNA are expressed within DA-containing neurons in the
VTA and SNc. In one series of experiments, we used dual
in situ hybridization (ISH) techniques to examine poten-
tial coexpression of mRNA for tyrosine hydroxylase (TH),
the rate-limiting enzyme for DA synthesis, with N/OFQ
and NOP mRNA in tegmental and nigral neurons. Addi-
tionally, we determined whether N/OFQ mRNA was colo-
calized with mRNAs for glutamic acid decarboxylase 65
and 67 (GAD), markers for -aminobutyric acid (GABA)
neurons. In another set of studies, N/OFQ and NOP
mRNA expression levels were measured in the SNc and
VTA after destruction of DA neurons with the neurotoxin
6-hydroxydopamine (6-OHDA). To determine whether the
density, functional activity, or both, of this G-protein–
coupled receptor (i.e., NOP) population was altered after
6-OHDA lesions, our final set of studies measured
N/OFQ-stimulated [35S]guanylyl-5-O-(-thio)-triphosphate
([35S]GTPS) binding VTA, SNc, and PFC.
MATERIALS AND METHODS
Adult male Sprague-Dawley rats (275–300 g, Charles
River, Wilmington, MA) were maintained and handled
according to NIH guidelines. All protocols used in the
present study were approved by the university unit for lab
animal medicine at the University of Michigan. The rats
were housed three per cage, maintained on a 12/12 hour
light/dark schedule (lights on at 6 AM, off at 6 PM), and
provided food and water ad libitum.
6-OHDA lesions
The rats were deprived of food 24 hours before surgery.
On the day of surgery, each rat was first injected with
atropine methyl nitrate (0.05 mg/kg, i.p., in 0.9% saline)
followed by an injection of desmethylimipramine (15 mg/
kg, i.p., in distilled water) and sodium pentobarbital
(30–60 mg/kg, i.p.). Each rat was then placed in a stereo-
taxic frame, and by using neurosurgical techniques, a
small hole was drilled through the skull. A 10-l Hamilton
syringe was lowered into the brain parenchyma and either
6-OHDA (2 mg/ml in 0.1 mg/ml ascorbic acid) or vehicle
(0.1 mg/ml ascorbic acid) was injected into the right me-
dial forebrain bundle at a rate of 0.5 l/min over an
8.25-minute period. The injection coordinates were 3.0
mm anterior to bregma, 1.8 mm right of the midline, and
8.3 mm ventral with respect to the surface of the skull
(Paxinos and Watson, 1986). Injections of 6-OHDA at
these coordinates were used to lesion both nigral and
tegmental dopamine neurons (Berridge and Robinson,
1998). After the 6-OHDA or vehicle injection, the microsy-
ringe was left in place for an additional 2 minutes and
then removed slowly. After surgical closure, each rat was
injected with warm 0.9% saline (3–6 cc, s.c.) and placed in
an incubator until it became ambulatory, after which it
was returned to an individual cage with food and water
supplied ad libitum. Fourteen days after the lesions, each
rat was decapitated; the brain rapidly was removed, fro-
zen in isopentane (40°), and stored at 80°C. Brains
were sectioned at 10 m in the coronal plane, mounted
onto polylysine-coated slides, and stored at 80°C.
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Synthesis of labeled riboprobes
35S-labeled riboprobes were used for single ISH experi-
ments, whereas both digoxigenin (dig) and 35S-labeled
riboprobes were used for dual ISH experiments. Ribo-
probes were generated for the NOP (700 base pairs, Neal
et al., 1999a), N/OFQ (580 base pairs, Neal et al., 1999b),
TH (300 base pairs, courtesy of Tong H. Joh, Cornell
University), GAD 65 (230 base pairs, courtesy of N.J.K.
Tillakaratne, University of California), and GAD 67 (210
base pairs, courtesy of A. Tobin, University of California-
Los Angeles). 35S-labeled and dig-labeled riboprobes were
generated with standard transcription reaction tech-
niques. These reactions were terminated with DNAse I for
15 minutes at room temperature. Probes labeled with 35S
and dig were separated from free nucleotides by means of
a Sephadex-G50 column. The dig-labeled fraction was de-
termined by means of a color reaction (see dual ISH meth-
ods for details).
Single radioactive ISH histochemistry
A detailed description of the radioactive ISH technique
has been described previously (see Watson et al., 1988).
Briefly, slide-mounted sections were removed from 80°C
and washed in the following solutions at room tempera-
ture: 4% formaldehyde solution for 1 hour, 3 times in 2	
standard saline citrate (SSC), 0.1 M triethanolamine (pH
8.0) and acetic anhydride (0.25%) for 10 minutes, and
water for 5 minutes. The slides were then dehydrated
though graded alcohols. The 35S-riboprobe was mixed with
filtered hybridization buffer for a final concentration of
1–2 	 106 dpm/35 l. Tissue sections were covered with
the 35S-riboprobe and hybridized in a 55°C oven over-
night. On day 2, the coverslips were removed and sections
were rinsed twice in 2	 SSC. Tissue was then treated
with RNase A solution followed by decreasing concentra-
tions of salt solutions and soaked in 0.1	 SSC for 1 hour
at 70°C. The sections were then rinsed in water, dehy-
drated in graded alcohols, and air-dried. Slides were ex-
posed to Biomax MR imaging film (Kodak) for the number
of days required to obtain an adequate signal (approxi-
mately 10 days for N/OFQ and NOP probes, 2–3 days for
TH probe). Brain images were captured with a CCD cam-
era (TM-745, Pulnix, USA). The slides were dipped in
NTB-2 emulsion, dried, and stored at 4°C for 1–3 weeks,
then developed (Kodak D-19), dehydrated in graded alco-
hols, and cover-slipped with mounting fluid (Permount).
Routine in situ control studies were performed on sec-
tions by treating with either (1) RNase A solution before
cRNA probe hybridization, or (2) 35S-labeled mRNA
(sense) strands. In all control studies, the radioactive sig-
nal did not differ from background.
Dual ISH histochemistry
Dig-labeled riboprobes were prepared as described
above. During the first 2 days, the double ISH protocol
was similar to the single ISH protocol. The only difference
was during the hybridization step, i.e., the dig-labeled and
35S-labeled probes were mixed together in hybridization
fluid. In the GAD experiments, both dig-labeled GAD67
and GAD65 probes were added to the hybridization fluid.
On day 2, after the 0.1	 SSC wash in 70°C, the slides were
cooled to room temperature in 0.1	 SSC. The slides were
then briefly placed in 0.1 M phosphate buffer (pH 7.4), and
transferred to carrageenin blocking solution (0.1 M phos-
phate buffer, 0.25% carrageenan, and 0.5% Triton-X 100
[pH 7.4]) for 1 hour at room temperature on a shaker. The
slides were then incubated overnight on a shaker in car-
rageenan blocking solution containing 1:20,000 alkaline
phosphatase (AP) -conjugated anti-digoxigenin antiserum
(Boehringer Mannheim). On day 3, sections were briefly
washed in 0.1 M phosphate buffer (pH 7.4) followed by
extensively washing in Tris-buffered saline (pH 7.5). The
sections were then placed in alkaline substrate buffer
(ASB; 100 mM Tris base, 150 mM NaCl, 50 mM MgCl2, pH
9.5) and underwent a color reaction in ASB solution con-
taining 5% polyvinyl [w/v], 0.45% 4-nitro blue tetrazolium
chloride (NBT; Boehringer Mannheim), 0.35% 5-bromo-4-
chloro-3-indoyl-phosphate (BCIP; Boehringer Mannheim),
and 0.024% levamisole (Sigma). The color reaction was
stopped when cells containing the dig label attained a
bright purple color. The sections were then washed in
water, placed in a 0.1 M glycine (pH 2.2)/0.5% Triton
X-100 solution, and fixed in 2.5% glutaraldehyde. The
slides were rinsed in water, dehydrated in graded alco-
hols, and exposed overnight to x-ray film to ensure the
presence of 35S-labeled probe. Sections were dipped in
Ilford KD-5 emulsion (Polysciences), stored in the dark at
4°C and developed after appropriate time lapse (approxi-
mately 2–3 weeks). Brain sections were visualized by us-
ing a Leica microscope (Leitz DMR, Wetzler, Germany)
connected to a camera (Sony DXC-970MD).




For detailed description of this technique, see Sim et al.
(1995). Briefly, slide-mounted sections were removed from
80°C and brought to room temperature 15–30 minutes
before use. Slides were transferred to humidifying cham-
bers with all incubations performed at room temperature.
Sections were initially incubated in 300 l of primary
assay buffer (50 mM Tris-HCl, 0.1% bovine serum albu-
min, 5 mM MgCl2, 1 mM EGTA, and 100 mM NaCl [pH
7.5]) for 10 minutes, followed by primary assay buffer
containing 2 mM guanosine diphosphate (GDP; Sigma, St.
Louis, MO) for 15 minutes. Sections were then incubated
in primary assay buffer containing 1 M cold GTPS
(Sigma) for 10 minutes and primary assay buffer for 10
minutes. The primary buffer was removed, and the sec-
tions were incubated for 2 hours in 300 l of incubation
medium (primary assay buffer containing 2 mM GDP,
0.04 nM 35S-GTPS [New England Nuclear, 1,250 Ci/
mM], 1 M DTT, protease inhibitor [0.1 mM phenylmeth-
ylsulfonyl fluoride, 1 g/ml aprotinin, 1 g/ml leupeptin, 1
g/ml pepstatin, and 1 mM iodoacetamide] and the chosen
agonist at varying concentrations). After incubation me-
dium, sections were rinsed in ice-cold Tris buffer (50 mM
Tris-HCl, pH 7.5), followed by ice-cold deionized water and
then air-dried. Slide-mounted sections were exposed to
Biomax MR imaging film (Kodak) for 20–48 hours, and
brain images were captured with a CCD camera (TM-745,
Pulnix, USA).
Agonist-stimulated GTPS binding controls
Basal binding was measured on sections incubated with
2 mM GTP and 0.04 nM [35S]GTPS in the absence of
agonist in the incubation medium. Agonist-stimulated
binding was measured with respect to basal binding in
adjacent sections. Basal binding was negligible in most
sections analyzed. Nonspecific binding was assessed when
10 M unlabeled GTPS was added to the incubation
medium containing 2 mM GTP and 0.04 nM [35S]GTPS
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in the presence of agonist. Specific binding was completely
eliminated when 10 M unlabeled GTPS added to the
incubation medium in the presence of N/OFQ.
Data Analysis
Percentage colocalization in the dual ISH studies was
calculated by dividing the number of dual-labeled neurons
by either 35S-labeled cells or dig-labeled cells 	 100. The
dig-labeled riboprobes appeared as a purple precipitate
under brightfield conditions, whereas 35S-labeled ribo-
probes appeared as silver grains under darkfield condi-
tions. Labeled neurons were counted at 40	 magnification
by using a grid. The percentage colocalization is reported
as the mean 
 SEM. For N/OFQ/TH dual ISH studies, six
brain sections (spanning from approximately bregma -5.2
to -6.04) were counted from each rat, with five to six rats
per group. For N/OFQ/GAD dual ISH studies, four brain
sections were counted from each rat with three rats per
group.
N/OFQ, NOP, and TH mRNA expression, as well as
N/OFQ-stimulated [35S]GTPS binding levels were deter-
mined with densitometric analysis. Each brain image
(captured from film) was analyzed individually by using
Scion Image (NIH image 1.61, Scion Corporation, Na-
tional Institutes of Health, Frederick, MD). For single ISH
studies, results are reported as the integrated density
(area of pixels above background multiplied by the mean
signal). Signal is a gray value at least 3.5 standard
deviations above background. For N/OFQ-stimulated
[35S]GTPS binding studies, results are reported as the
integrated density values obtained for stimulated sections
minus the integrated density values from basal sections
(sections adjacent to stimulated sections).
Significance of differences in [35S]GTPS binding,
N/OFQ and NOP mRNA values after 6-OHDA lesions was
computed by using a one-way analysis of variance. All
significant effects were further analyzed with Tukey-
Kramer multiple comparisons test.
RESULTS
TH, N/OFQ, and NOP mRNA expression in
the SNc and VTA
The distribution pattern of TH, GAD, N/OFQ, and NOP
mRNA in the VTA and SNc was consistent with published
studies (Chesselet et al., 1987; Esclapez et al., 1993, 1994;
Sherman and Moody, 1995; Neal et al., 1999a, b). TH
mRNA was expressed throughout the VTA and SNc. In
contrast, GAD mRNA was found in a small population of
neurons in these midbrain regions. NOP and N/OFQ
mRNA was also found throughout the VTA and SNc, but
these mRNAs exhibited varying degrees of expression
within the subnuclei. Within the SNc, N/OFQ mRNA was
present throughout medial and dorsal divisions, and
slightly higher levels were found in the pars lateralis.
Within the VTA, N/OFQ-containing cells were present
throughout the region with a dense expression found in
the paranigral subnuclei.
Orphanin receptor mRNA distribution was similar to
that described for N/OFQ mRNA with a few notable ex-
ceptions. Within the SNc, NOP mRNA levels were high in
ventral regions and lower levels were found in the dorsal
compacta and pars lateralis. Expression of NOP mRNA
was distributed throughout the VTA proper, with high
levels noted in the parabrachial and paranigral nuclei and
lower levels in the interfascicular nuclei. Within each
region analyzed, NOP mRNA had a more diffuse distribu-
tion whereas N/OFQ was heavily concentrated in individ-
ual neurons throughout the VTA and SNc.
Colocalization patterns between TH mRNA
and either N/OFQ or NOP mRNA
Within the VTA (Figs. 1A, 2A–D), virtually none of the
TH-positive neurons expressed N/OFQ mRNA (1.9 

0.3%, n  6) and only a small portion of the N/OFQ-
containing neurons expressed TH mRNA (10.5 
 1.0%,
n  6). In contrast, approximately 50% of TH neurons
contained NOP mRNA expression (47.9 
 2.0%, n  6)
and nearly 80% of NOP-positive neurons exhibited TH
mRNA expression (77.0 
 2.7%, n  6).
The pattern of TH colocalization with N/OFQ and NOP
mRNAs in the SNc was similar to that observed in the
Fig. 1. Bar graphs representing the percentage coexpression of
tyrosine hydroxylase (TH) mRNA with either nociceptin/orphanin FQ
(N/OFQ) or N/OFQ receptor (NOP) mRNA in the ventral tegmental
area (VTA) and substantia nigra compacta (SNc). A: Within the VTA,
few TH-positive neurons exhibited N/OFQ mRNA signal, whereas a
small population of N/OFQ neurons also expressed TH mRNA.
Roughly 50% of TH-positive neurons coexpressed NOP mRNA, and
approximately 80% of NOP-positive neurons also contained TH
mRNA signal. B: Within the SNc, few neurons that expressed N/OFQ
mRNA were positive for TH mRNA and vice versa. Almost half of the
TH-containing neurons also contained NOP mRNA and nearly 75% of
the neurons that expressed NOP mRNA also expressed TH mRNA.
The bars represent the percentage of 35S-labeled neurons containing
digoxigenin label and vice versa. Values are the mean 
 SEM.
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VTA (Figs. 1B, 2A–D). Few TH-containing neurons ex-
pressed N/OFQ mRNA (1.3 
 0.2%, n  6), and few
N/OFQ-containing neurons were positive for TH mRNA
(6.3 
 0.9%, n  6). Roughly half of the TH-containing
neurons expressed NOP mRNA (44.6 
 2.0%, n  6), and
approximately 75% of the neurons expressing NOP mRNA
also expressed TH mRNA (73.9 
 2.1%, n  6).
N/OFQ and NOP mRNA expression in the
VTA and SNc after 6-OHDA lesions
TH mRNA levels were assessed first to determine the
extent of the lesion. Five of the 12 animals had an 85 and
95% loss of TH mRNA in the VTA and SNc, respectively,
on the 6-OHDA–lesioned side compared with sham-
lesioned controls. Tissue from these five rats was used for
evaluation of [35S]GTPS binding, GAD, N/OFQ, and NOP
mRNA values.
In the VTA, N/OFQ mRNA expression was roughly 60%
higher on the 6-OHDA-lesioned side (3,411.3 
 473.7)
compared with sham-lesioned controls (2,105.4 
 191.2,
n  5, P  0.05) or the contralateral side (2,067.7 
 352.0,
n  5, P  0.05, Figs. 3B, 4A). In the SNc, N/OFQ mRNA
levels were approximately three-fold higher in the
6-OHDA–lesioned side (12,415.9 
 2,438.9) compared
with sham-lesioned controls (4,285.6 
 455.8, n  5, P 
0.01) or the contralateral side (3,802.8 
 578.9, n  5, P 
0.01, Figs. 3B, 4A).
In contrast to the changes in N/OFQ mRNA expression
in the VTA, NOP mRNA was almost 80% lower on the
6-OHDA–lesioned side (768.4 
 186.4, n  5) when com-
pared with sham-lesioned controls (3,439.2 
 431.4, n  5,
P  0.05) or the contralateral control side (3,718.9 

849.6, n  5, P  0.01; Figs. 3C, 4B). The same holds true
for the 6-OHDA lesion effect in the SNc (Figs. 3C, 4B)
where NOP mRNA expression was nearly 85% lower on
the 6-OHDA-lesioned side (722.8 
 150.2, n  5) when
measured against sham-lesioned controls (4,365.3 

621.7, n  5, P  0.01) or the contralateral side (4,639.8 

675.8, n  5, P  0.01).
N/OFQ mRNA levels in the sham-lesioned controls did
not differ significantly from the contralateral side (VTA,
1,920.6 
 127.3; SNc, 4235.8 
 494.0, n  5). Similarly,
NOP mRNA levels on the sham-lesioned control side did
not differ significantly from the contralateral side (VTA,
4,205.3 
 486.9; SNc, 4,861.7 
 752.9, n  5).
Colocalization patterns between GAD and
N/OFQ mRNA
As stated above, the majority of N/OFQ-containing neu-
rons did not contain TH mRNA signal; therefore, a
follow-up set of studies determined whether N/OFQ
mRNA was colocalized with GAD mRNA in VTA and SNc.
Within the VTA (Fig. 5A), a large portion of N/OFQ-
positive neurons also expressed GAD mRNA (57.8 
 9.4%,
Fig. 2. Photomicrographs of dual in situ hybridization experi-
ments comparing colocalization of either 35S-labeled nociceptin/
orphanin FQ (N/OFQ) or N/OFQ receptor (NOP) neurons (silver
grains) with digoxigenin-labeled tyrosine hydroxylase (TH) neurons
(purple precipitate) in the ventral tegmental area (VTA) and substan-
tia nigra compacta (SNc). A: Most N/OFQ-positive neurons did not
contain signal for TH mRNA. B: High-magnification photomicrograph
of TH and N/OFQ mRNA expression patterns in the VTA. C: Many
NOP-positive neurons contained signal for TH mRNA. D: High-mag-
nification photomicrograph of TH and NOP mRNA expression pat-
tern. Arrows in A and C indicate the area seen in B and D, respec-
tively. Scale bar  300 m in A (applies to A,C), 60 m in B (applies
to B,D).
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n  3). A similar situation was noted in the SNc (Fig. 5A),
where approximately half of the N/OFQ-positive neurons
contained GAD mRNA (51.7 
 8.3%, n  3).
The percentage of OFQ-positive neurons that expressed
GAD mRNA was analyzed in the SNc after 6-OHDA le-
sions (Fig. 6). This percentage was similar on the
6-OHDA–lesioned side (40.5 
 1.6%, n  3) compared
with sham-lesioned controls (45.3 
 8.3%, n  3) or the
contralateral sides (lesion, 38.6 
 2.5%, n  3; sham,
44.4 
 9.7%, n  3). Similar studies were performed in the






In the VTA, N/OFQ-stimulated [35S]GTPS binding was
much lower on the 6-OHDA–lesioned side (767.4 
 283.0,
n  5) compared with the sham-lesioned controls
(6,871.8 
 1,522.5, n  5, P  0.004; Fig. 7A). In this case,
N/OFQ-stimulated [35S]GTPS binding was reduced on
the contralateral side of the 6-OHDA lesion (3,151.6 

1,107.6, n  5) when compared against the contralateral
side of sham-lesioned controls (7,745.2 
 1,716.7, n  5,
P  0.02). In the SNc, N/OFQ-stimulated [35S]GTPS
binding was lower on the 6-OHDA-lesioned side
(2,014.2 
 537.3, n  6) when measured against the sham-
lesioned controls (6,742.2 
 1,155.3, n  5, P  0.02) or
the contralateral side (5,177.2 
 665.3, n  6; Fig. 7A). In
the SNc, N/OFQ-stimulated [35S]GTPS binding on the
sham-lesioned side did not differ from the contralateral
side (6,723.6 
 1,412.9, n  5).
In the PFC (Fig. 7B), N/OFQ-stimulated [35S]GTPS
binding was similar on the 6-OHDA–lesioned side
(45,947.1 
 6,542.3, n  4) when measured against sham-
lesioned controls (54,095.8 
 7,484.9, n  4) or the con-
tralateral side (47,064.6 
 5,301.0, n  4). Additionally,
N/OFQ-stimulated [35S]GTPS binding in the sham-
lesioned control did not differ significantly (P  0.05) from
the contralateral side (47,967.6 
 7,323.2, n  4).
DISCUSSION
In this study, we used two convergent approaches to
characterize the anatomic relationship between the or-
phanin and DA systems in the brain: 6-OHDA lesions and
dual ISH. Both approaches have led to consistent conclu-
sions. In the VTA and SNc, many TH neurons expressed
NOP mRNA and a majority of NOP-positive neurons also
contained TH mRNA (Figs. 1A,B, 2C,D). In contrast, only
a small percentage of TH neurons expressed N/OFQ
mRNA and relatively few N/OFQ neurons expressed TH
mRNA (Figs. 1A,B, 2A,B). Additional experiments demon-
strated that N/OFQ mRNA was colocalized with GAD
mRNA in these regions (Fig. 5). Accordingly, NOP mRNA
was located on tegmental and nigral dopaminergic neu-
rons, whereas N/OFQ mRNA was found on GABA neu-
rons.
In agreement with the colocalization observations,
N/OFQ mRNA increased while NOP mRNA decreased in
the VTA and SNc after 6-OHDA lesions (Figs. 3, 4). Fur-
thermore, N/OFQ-stimulated [35S]GTPS binding de-
creased in the VTA and SNc on the 6-OHDA-lesioned side
Fig. 3. Digitized photomicrographs of tyrosine hydroxylase (TH),
nociceptin/orphanin FQ (N/OFQ), and N/OFQ receptor (NOP) mRNA
in the ventral tegmental area (VTA) and substantia nigra compacta
(SNc) after unilateral 6-hydroxydopamine (6-OHDA) lesions. The ar-
row points to the side that received the 6-OHDA injection. The SNc
and VTA are outlined in black on the 6-OHDA–lesioned side. A: TH
mRNA expression decreased on the side subjected to a 6-OHDA in-
jection. B: Expression of N/OFQ mRNA increased on the 6-OHDA–
lesioned side. C: Expression of NOP mRNA decreased on the
6-OHDA–lesioned side. Scale bar  1 mm in A–C.
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(Fig. 7A). In contrast, N/OFQ-stimulated [35S]GTPS
binding was unaltered in the PFC, a DA terminal region,
after 6-OHDA lesions (Fig. 7B). The results from these
experiments would suggest the NOP is found on the cell
bodies of DA neurons in the midbrain.
A majority of the neurons originating in the VTA and
SNc contain DA, whereas approximately 20–25% of the
neurons are nondopaminergic and contain neurotransmit-
ters such as GABA, CCK, or both (Swanson, 1982; Parent
and Hazrati, 1995). As stated above, only a small popula-
tion of N/OFQ mRNA was present on nigral and tegmen-
tal DA neurons (10%), whereas a larger portion was
found on GABAergic neurons (50–60%). Although the
number of GABAergic neurons in the SNc and VTA is
small (Chesselet et al., 1987), these large neurons are
known to exert local influence onto DA neurons as well as
send projections to areas such as the thalamus and visual
cortex (for review, see Fallon and Loughlin, 1995). The
present study phenotyped the majority of the N/OFQ neu-
rons in the VTA and SNc; however, a portion of cells
containing N/OFQ mRNA may not have been identified. It
is possible that neurons expressing low amounts of GAD
mRNA may not have been detected with the nonradioac-
tive ISH technique, thereby underrepresenting the total
population of N/OFQ neurons that express GAD mRNA
(see Day et al., 1999). Another feasible explanation is that
N/OFQ mRNA is found in astrocytes and is regulated by
ciliary neurotrophic factor (Buzas et al., 1998, 1999). As
pointed out by Buzas et al. (1999), N/OFQ may play a role
in neurotrophic responses to neural injury and the N/OFQ
mRNA increase observed in the present study may be in
response to the loss of cells in the VTA and SNc after the
6-OHDA lesion. Future studies will need to determine
whether N/OFQ mRNA is also colocalized with markers
for astrocytes (i.e., glial fibrillary acidic protein).
Roughly half of the identified DA neurons also ex-
pressed NOP mRNA, and, as would be expected, lesions
specific to DA neurons diminished this mRNA pool (Figs.
3, 4). The expression of NOP mRNA changed markedly in
both midbrain regions, but there is a slightly greater re-
duction of NOP mRNA in the SNc as opposed to the VTA
(Fig. 4B). Dopamine neurons in the VTA are known to be
somewhat resistant, compared with DA neurons in the
SNc, to the neurotoxin 6-OHDA. Specific coordinates were
chosen to optimize the destruction of both tegmental and
nigral DA-containing neurons (Berridge and Robinson,
1998), resulting in greater than 85 and 95% lesion in the
VTA and SNc, respectively. Although the extent of the
6-OHDA lesion would be considered massive (Schwarting
and Huston, 1996), the greater reduction of NOP mRNA in
the SNc may be the result of a more pronounced loss of DA
neurons. One cannot discount the possibility that the sur-
viving DA neurons, the small population (approximately
20%) of nondopaminergic neurons, or both, had altered
NOP mRNA production subsequent to the neurotoxic in-
sult (all alterations in NOP mRNA, increases or decreases,
would have contributed to our overall results). However,
in light of our finding that nearly 80% of NOP mRNA was
colocalized with TH mRNA and alterations in NOP mRNA
after DA lesions correlated closely with the extent of DA
neuronal loss, it seems reasonable to conclude that the
NOP mRNA decreases after 6-OHDA lesions was due to
the specific loss of NOP mRNA-containing dopaminergic
neurons.
The complex neuroanatomic organization of DA projec-
tions systems has been worked out in detail (for review,
see Swanson, 1982; Oades and Halliday, 1987; Joel and
Weiner, 2000). In brief, the mesostriatal DA system orig-
inates in the SNc and projects primarily to the dorsal
striatum (STR). The mesostriatal system also includes the
projections from the VTA to the anteromedial STR. The
mesolimbic DA system originates in the VTA and projects
mainly to the nucleus accumbens (NAc) but also inner-
vates areas such as the olfactory tubercles (Tu), bed nu-
cleus of the stria terminalis (BNST), amygdala (AM), and
lateral septum (LS). The mesocortical DA system origi-
nates in the VTA and extends largely to the prefrontal,
cingulate, and entorhinal cortices.
As presented herein, only a small percentage of DA
neurons within the mesostriatal, mesolimbic, and meso-
cortical systems contain signal for N/OFQ mRNA. Hence,
it was not surprising that lesions targeting DA neurons
did not decrease N/OFQ mRNA expression levels. In fact,
Fig. 4. Bar graphs illustrating the effects of a unilateral
6-hydroxydopamine (6-OHDA) lesion on nociceptin/orphanin FQ (N/
OFQ) and N/OFQ receptor (NOP) mRNA in the ventral tegmental
area (VTA) and substantia nigra compacta (SNc). A: N/OFQ mRNA
was significantly increased in 6-OHDA–lesioned side compared with
the sham-treated side in the VTA and SNc. B: NOP mRNA was
significantly decreased in 6-OHDA–lesioned side compared with the
sham-treated side in the VTA and SNc. Sham-treated sides do not
differ from contralateral sides in either sham or 6-OHDA–lesioned
rats. Rats that had received 85 and 95% lesion (as determined by
tyrosine hydroxylase mRNA analysis) in the VTA and SNc, respec-
tively, were used to quantify changes in N/OFQ and NOP mRNA.
Values are the mean 
 SEM.
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N/OFQ mRNA expression levels increased after the lesion
and this increase was much greater in the SNc compared
with the VTA (Fig. 4A). Furthermore, the percentage of
N/OFQ neurons expressing GAD mRNA (Fig. 6) and the
number of N/OFQ-positive neurons (data not shown) did
not change significantly after the lesion, suggesting that
the increase in N/OFQ mRNA expression was largely due
to an increase in the amount of mRNA in cells already
expressing N/OFQ mRNA rather than a recruitment of a
new population of cells.
The greater response of N/OFQ mRNA in the SNc com-
pared with the VTA may be due to a more pronounced
lesion in the SNc (similar to the NOP ISH studies). As
pointed out by Schwarting and Huston (1996), most
changes postsynaptic to DA neurons occur only when
there is a substantial lesion of DA neurons and the near
total loss of striatal DA innervation disrupts feedback
pathways that project to the nigral DA neurons. These
feedback pathways include projections from the STR, NAc
core, and dorsolateral ventral pallidum (Heimer et al.,
1991; Zahm, 1989). Additionally, the subthalamic nucleus
projects primarily to the SNreticulata (some minor projec-
tions may extend to the SNc), and these SNreticulata
neurons are known to have extensive anatomic interac-
tions with the cell bodies and long dendrites of DA neu-
rons (for review see Joel and Weiner, 2000). The 6-OHDA
lesions observed in the present study may have led to
altered feedback control which, in turn, could have re-
sulted in the large increase in N/OFQ mRNA expression
levels.
Although NOP mRNA was found in DA neurons within
the mesolimbic and mesocortical systems, the site of re-
ceptor protein expression could be in the DA cell body or
terminal region (or both). Indeed, binding studies support
Fig. 5. Bar graph representing the percentage coexpression of
nociceptin/orphanin FQ (N/OFQ) with glutamic acid decarboxylase
(GAD) mRNA in the ventral tegmental area (VTA) and substantia
nigra compacta (SNc). A: Approximately 50–60% of N/OFQ-positive
neurons contained GAD mRNA signal. Values are the mean 
 SEM.
B: A photomicrograph of a dual in situ hybridization experiment
comparing the colocalization of 35S-labeled N/OFQ neurons (silver
grains) with digoxigenin-labeled GAD neurons (purple precipitate) in
the SNc. The black arrow points to a 35S-labeled neuron only, whereas
the open arrow points to a neuron containing both labels. Scale bar 
40 m in B.
Fig. 6. Bar graph illustrating the effects of unilateral
6-hydroxydopamine (6-OHDA) lesions on the percentage of nociceptin/
orphanin FQ (N/OFQ) neurons that expressed glutamic acid decar-
boxylase mRNA in the substantia nigra compacta (SNc). The levels of
colocalization were not altered on the side that received the 6-OHDA
lesion compared with the sham-lesioned side. Values are the mean 

SEM.
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the existence of the NOP in brain regions associated with
both DA cell bodies and terminals (Neal et al., 1999a). It
should be noted that the presence of binding in the DA
regions does not indicate whether the receptor is located
presynaptically, on the DA cell body or terminal itself,
postsynaptically on DA receptive neurons, or possibly
even on adjacent but non–DA-related cell bodies or termi-
nals. Nonetheless, N/OFQ binding levels are low in the
VTA and low to moderate in several DA projection areas,
including the NAc, Tu, LS, and AM (Neal et al., 1999a). In
contrast, these binding levels are moderate to high in the
BNST and entorhinal cortex and dense in the prefrontal,
cingulate, and frontal cortices (Neal et al., 1999a). Simi-
larly, N/OFQ-stimulated [35S]GTPS binding is low in the
VTA, NAc, LS, BNST, and all areas of the AM. The high-
est levels of N/OFQ-stimulated [35S]GTPS binding are
found in cingulate and frontal cortices (Shimohira et al.,
1997; Sim and Childers, 1997). These studies suggest that
the NOP protein is present and highly activatable in the
cortex as opposed to the other projection areas within the
mesolimbic and mesocortical DA systems.
Another conclusion may be drawn when considering the
mesostriatal DA system. NOP binding with 125I-[14Tyr]-
N/OFQ is situated throughout the SNc while absent in the
STR (Neal et al., 1999a), but N/OFQ stimulated
[35S]GTPS binding is low in both the SNc and STR (Shi-
mohira et al., 1997; Sim and Childers, 1997). Thus, NOP
may be expressed on mesostriatal DA cell bodies, as op-
posed to terminals, but it is uncertain to what extent these
receptors are functional.
Although the current study did not systematically com-
pare N/OFQ-stimulated [35S]GTPS binding across all
brain regions associated with DA circuitry, it is clear that
after a 6-OHDA lesion, binding was dramatically reduced
in the VTA and SNc but not in the PFC, the main terminal
projection region of the DA mesocortical system. Levels
were not evaluated in the NAc or STR because low to
nearly nonexistent (in the case of the STR) levels of
N/OFQ-stimulated [35S]GTPS binding were found in
these areas. Current studies in our laboratory (MH
Miquel Kabbaj, personal communication) show alterations
in N/OFQ-stimulated [35S]GTPS binding could be due to
changes in the number of receptors available, the coupling
efficiency of the receptor, and/or number of G-proteins
present. The large reduction in NOP mRNA combined
with the specific loss in binding in the cell body vs. the
projection areas after a 6-OHDA lesion would suggest a
differential expression of NOP protein in the soma as
opposed to terminals.
The high levels of 125I-[14Tyr]-N/OFQ binding and
N/OFQ-stimulated [35S]GTPS binding in the cortical re-
gions (Neal et al., 1999a) is most likely due to the NOP
located on nondopaminergic neurons within these regions.
Alternatively, NOP proteins originating in the DA neu-
rons may be transported to DA terminals in the PFC;
however, this may represent a small subpopulation of the
total pool of NOP in the cortex. In this scenario, the loss of
such a subpopulation after 6-OHDA lesions may not be
detected by this technique. Taken together, the orphanin
system may interact with mesencephalic DA systems di-
rectly by means of its receptor on DA cell bodies and
dendrites and indirectly through its receptor on adjoining
circuitry at the level of the terminal.
Although changes in mRNA levels correlated with the
extent of the 6-OHDA lesion, alterations in N/OFQ-
stimulated [35S]GTPS binding did not (Fig. 7A). In other
words, the decrease in N/OFQ-stimulated [35S]GTPS
binding was not as great in the SNc compared with the
VTA. The receptors remaining in the SNc may have an
increased coupling capacity to compensate for the dra-
matic loss of receptors, leading to slightly higher binding
levels. Clearly, the ISH studies demonstrated that N/OFQ
mRNA increased to a much greater extent in the SNc
compared with the VTA. Assuming the mRNA was trans-
lated into protein, the higher levels of peptide in the SNc
could have influenced the functional activity of the resid-
ual receptors.
Our observations suggest that the orphanin system is in
an anatomic position to influence DA neuronal activity,
supporting recent studies demonstrating N/OFQ influence
on DA release. For example, 3 and 30 g of N/OFQ (i.c.v.)
decreases accumbal DA levels (measured with microdialy-
sis) by 25 and 50% of baseline values, respectively (Mur-
phy et al., 1996). Placement of N/OFQ (1 mM) into the
VTA increases tegmental GABA, glutamate, and aspar-
tate while decreasing basal DA levels by 40% in the NAc
(Murphy et al., 1999). Local N/OFQ (0.1–10 M) admin-
istration of 1- and 10-M increases striatal DA levels by
383 and 398%, respectively (Konya et al., 1998). Interest-
Fig. 7. Bar graphs illustrating the effects of unilateral
6-hydroxydopamine (6-OHDA) lesions on nociceptin/orphanin FQ (N/
OFQ) -stimulated [35S]GTPS binding in the ventral tegmental area
(VTA), substantia nigra compacta (SNc), and prefrontal cortex (PFC).
A: N/OFQ-stimulated [35S]GTPS binding in the VTA and SNc was
reduced on the side subjected to a 6-OHDA lesion. B: N/OFQ-
stimulated [35S]GTPS binding in the PFC was not altered on the
6-OHDA–lesioned side compared with the sham-lesioned side. Values
are the mean 
 SEM.
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ingly, N/OFQ (10 nmol, i.c.v.) reduces morphine-induced
(5 and 10 mg/kg, i.p.) DA release in the NAc as measured
by in vivo voltametry (Di Giannuario et al., 1999). Our
current findings suggest a mechanism for this modulation:
activation of NOP may directly inhibit DA neuronal activ-
ity at the level of the cell body and indirectly excite DA
activity at the level of the terminal by means of disinhi-
bition of adjoining circuitry (e.g., GABA).
The presence of the orphanin peptide and receptor in
the mesostriatal DA system might suggest some involve-
ment with sensorimotor functions (Graybiel et al., 1994).
Indeed at low and high doses, N/OFQ augments and in-
hibits locomotion, respectively (Reinscheid et al., 1995;
Devine et al., 1996b; Florin et al., 1996). Moreover, a high
dose of N/OFQ (10 nmol, i.c.v.) interferes with fine and
gross motor coordination (Devine et al., 1996b). Orphanin
FQ may be acting on the mesostriatal DA system to influ-
ence locomotion (Konya et al., 1998), but, as pointed out by
Devine and colleagues (1996b), N/OFQ may be acting at
several key regions involved in motor function (i.e., brain-
stem and basal ganglia).
The mesolimbic and mesocortical DA systems are impli-
cated in motivation and reward (Le Moal and Simon,
1991; Bardo, 1998; Schultz, 1998), and, although N/OFQ
alters DA release, N/OFQ (0.1–100 nmol, i.c.v.) does not
appear to produce conditioned place preference or aver-
sion (Devine et al., 1996a). However, N/OFQ (3 and 10
nmol, i.c.v.) impairs acquisition of morphine and alcohol
conditioned place preference (Ciccocioppo et al., 1999;
Murphy and Maidment, 1999b). In these studies, N/OFQ
can influence several brain regions, due to the route of
N/OFQ administration (i.c.v.), possibly confounding the
findings. Although the role of the orphanin system in
mediating mesocorticolimbic DA systems and, therefore,
possibly interfering with motivational states remains to
be fully determined, our findings lay some of the anatomic
groundwork for understanding this complex interplay.
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